Oncology Institute Q1 revenue up 24% to $95M; net loss narrows to $19.9M

Oncology Institute, Inc.

2024-Q1 EPS reported -$0.22 revenue$94,666,000

Revenue of $95M (+24.2% YoY); net loss $19.9M vs $30.0M loss in prior year.
Gross profit $12M (-15.1% YoY); gross margin 12.6% vs 18.5% a year ago.
Adjusted EBITDA loss of $10.9M vs $7.4M loss in prior year quarter.
Signed 7 new value-based contracts; reaffirmed full-year 2024 guidance.
Ended Q1 with 73 clinics, 126 providers; scripts dispensed up 70% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oncology Institute, Inc. reported three months ended March 31, 2024 results: revenue $95 million, net income Net loss of $19.9 million, EPS $(0.22) and $(0.22). Guidance reaffirmed.

Period: three months ended March 31, 2024
Revenue: $95 million
Net income: Net loss of $19.9 million
EPS: $(0.22) and $(0.22)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Officer • Hired 7 new providers in the quarter and ended the quarter with 73 clinics and 126 employed providers First Quarter 2024 Financial Highlights • Consolidated revenue of $95 million, an increase of 24.2% from $76 million compared to the prior year quarter • Gross profit of $12 million, a decrease of 15.1% compared to the prior year quarter, and gross margin

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-023189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.